Comparative Safety Signals for Melanoma Checkpoint Inhibitors Across Trials and FAERS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Chen Y, Liang X, Chen X, et al.
Jul 29, 2026 · Published in: Health Science Reports
Immune checkpoint inhibitors in melanoma: safety profiles unveiled.
Venetoclax TDM Reduces Toxicity Risk in Posaconazole-Treated AML Patients
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Sani B, Cignetti A, Leporati M, et al.
Jul 25, 2026 · Published in: Oncology Research
Venetoclax levels spike with posaconazole: TDM is essential.
Daraxonrasib Halves Death Risk in Previously Treated Pancreatic Cancer
Analysis Oncology Pharmacy Practice-changing Grade: Moderate
O'Reilly EM, Wainberg ZA, Hendifar AE, et al.
Jul 23, 2026 · Published in: The New England Journal of Medicine
Daraxonrasib doubles survival in metastatic pancreatic cancer.
Immunotherapy May Enable Safe Axillary De-escalation in Node-Positive TNBC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li Z, Qu Z, Pei S, et al.
Jul 23, 2026 · Published in: Frontiers in Immunology
Chemo-immunotherapy may enable less invasive breast cancer surgeries.
Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Standard-Risk Myeloma
Analysis Oncology Pharmacy Practice-changing Grade: Moderate
Kumar S, Jacobus S, Cohen A, et al.
Jul 16, 2026 · Published in: N Engl J Med
Two-year lenalidomide is as effective as indefinite therapy in multiple myeloma.
Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Feng X, Ao Y, Wang L, et al.
Jul 14, 2026 · Published in: Frontiers in Immunology
Adjuvant therapies improve survival in high-risk liver cancer patients.
Transporters and CYP3A4 Shape Daraxonrasib Brain and Plasma Exposure
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Arguedas D, Bui V, Law T, et al.
Jul 8, 2026 · Published in: Pharmacological Research
Transporter interactions may challenge daraxonrasib's effectiveness against brain metastases.
Immune Checkpoint Inhibitors Redefine First-Line Cholangiocarcinoma Therapy
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Nisa FU, Ali M, Khan T, et al.
Jul 6, 2026 · Published in: Journal of the Egyptian National Cancer Institute
Immune checkpoint inhibitors redefine advanced cholangiocarcinoma treatment.
Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Wang Y, Tang SC
Jun 27, 2026 · Published in: Critical Reviews in Oncology/hematology
Targeted cancer therapies revolutionize personalized oncology treatment.
Ivonescimab Beats Tislelizumab on Survival in Squamous Lung Cancer
Analysis Oncology Pharmacy Practice-changing Grade: High
Lu S, Liu B, Luo Y, et al.
Jun 27, 2026 · Published in: Lancet (London, England)
Ivonescimab enhances survival in squamous NSCLC, offering new hope.
Variant-Stratified ALK Inhibitor Selection in EML4-ALK Lung Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Low
Li S, Bao L, Zhou D, et al.
Jun 26, 2026 · Published in: Technology in Cancer Research & Treatment
EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.
Sequencing Systemic Therapy in Resectable NSCLC: Equipoise Remains
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Osarogiagbon RU, Cetnar JP, Aljumaily R
Jun 23, 2026 · Published in: American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
New trials may refine lung cancer therapy timing strategies.
KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities
Analysis Oncology Pharmacy Confirmatory Grade: Low
Izzedine H, Perazella MA, Kuruvada KM, et al.
Jun 20, 2026 · Published in: Kidney International
Preventing kidney damage in cancer treatment requires proactive strategies.
Venetoclax-Based Regimens Reshape Chemotherapy-Free CLL Management
Analysis Oncology Pharmacy Confirmatory Grade: Very Low
Kegyes D, Muresan X, Bancos A, et al.
Jun 11, 2026 · Published in: Critical Reviews in Oncology/hematology
Venetoclax brings new promise to chronic lymphocytic leukemia management.
Daraxonrasib Shows Early Activity in RAS-Mutated Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wolpin BM, Park W, Garrido-Laguna I, et al.
May 7, 2026 · Published in: The New England Journal of Medicine
Daraxonrasib shows promise in advanced RAS-mutated pancreatic cancer.